Journal of Current Glaucoma Practice

Register      Login

VOLUME 17 , ISSUE 2 ( April-June, 2023 ) > List of Articles


New-onset Glaucoma Following Moderna COVID-19 Vaccination

Yi-Wen Su, Shih-Jung Yeh, Mei-Ju Chen

Keywords : Adverse event, COVID-19 vaccine, Glaucoma, Moderna

Citation Information : Su Y, Yeh S, Chen M. New-onset Glaucoma Following Moderna COVID-19 Vaccination. J Curr Glaucoma Pract 2023; 17 (2):106-109.

DOI: 10.5005/jp-journals-10078-1408

License: CC BY-NC 4.0

Published Online: 11-07-2023

Copyright Statement:  Copyright © 2023; The Author(s).


Aim: To report a case of new-onset glaucoma following administration of the Moderna (mRNA-1273) vaccine. Background: Previous studies have reported a low incidence of ocular adverse events induced by the coronavirus disease 2019 (COVID-19) vaccine. The literature on open-angle glaucoma associated with COVID-19 vaccination is limited. Case description: The patient complained of blurred vision 2 days following the administration of the second dose of the Moderna vaccine in July 2021. At presentation, the ophthalmic examination showed elevated intraocular pressure (IOP) of 30 mm Hg in her right eye (OD) and 18 mm Hg in her left eye (OS). There were no signs of intraocular inflammation or glaucomatous optic neuropathy at the initial presentation. She was treated with a topical β-blocker first. In addition, 1 month later, her IOPs were 28 mm Hg OD and 26 mm Hg OS. Although treated with multiple antiglaucoma medications, her optic cup-to-disc ratios were increased in both eyes (OU) compared to May 2019. She developed a glaucomatous visual field (VF) defect OD in October 2021. Optical coherence tomography (OCT) revealed progressive retinal nerve fiber layer (RNFL) thinning in OU. Conclusion: Glaucoma may be a rare but severe ocular adverse event of the Moderna vaccines. The ophthalmologist should pay attention to the risk of increased IOP following COVID-19 vaccination. Clinical significance: We reported a case of new-onset open-angle glaucoma presumably associated with COVID-19 vaccination.

  1. WHO Coronavirus Disease (COVID-19) Dashboard. World Health Organization; Available from:
  2. Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA vaccine against SARS-CoV-2 - preliminary report. N Engl J Med 2020;383(20): 1920–1931. DOI: 10.1056/NEJMoa2022483
  3. Gargano JW, Wallace M, Hadler SC, et al. Use of mRNA COVID-19 vaccine after reports of myocarditis among vaccine recipients: update from the advisory committee on immunization practices - United States, June 2021. MMWR Morb Mortal Wkly Rep 2021;70(27):977–982. DOI: 10.15585/mmwr.mm7027e2
  4. Cheng JY, Margo CE. Ocular adverse events following vaccination: overview and update. Surv Ophthalmol 2022;67(2):293–306. DOI: 10.1016/j.survophthal.2021.04.001
  5. Singh RB, Parmar UPS, Cho W, et al. Glaucoma cases following SARS-CoV-2 vaccination: a VAERS database analysis. Vaccines (Basel) 2022;10(10): DOI: 10.3390/vaccines10101630
  6. Mahabadi N, Foris LA, Tripathy K. Open Angle Glaucoma. StatPearls. Treasure Island (FL): StatPearls Publishing Copyright © 2022, StatPearls Publishing LLC. 2022.
  7. Ng XL, Betzler BK, Ng S, et al. The eye of the storm: COVID-19 vaccination and the eye. Ophthalmol Ther 2022;11(1):81–100. DOI: 10.1007/s40123-021-00415-5
  8. Wu P, Duan F, Luo C, et al. Characteristics of ocular findings of patients with coronavirus disease 2019 (COVID-19) in Hubei Province, China. JAMA Ophthalmol 2020;138(5):575–578. DOI: 10.1001/jamaophthalmol.2020.1291
  9. Yan Y, Diao B, Liu Y, et al. Severe acute respiratory syndrome coronavirus 2 nucleocapsid protein in the ocular tissues of a patient previously infected with coronavirus disease 2019. JAMA Ophthalmol 2020;138(11):1201–1204. DOI: 10.1001/jamaophthalmol.2020.3962
  10. Zhou X, Zhou YN, Ali A, et al. Case report: a re-positive case of SARS-CoV-2 associated with glaucoma. Front Immunol 2021;12:701295. DOI: 10.3389/fimmu.2021.701295
  11. Bakadia BM, Boni BOO, Ahmed AAQ, et al. The impact of oxidative stress damage induced by the environmental stressors on COVID-19. Life Sci 2021;264:118653. DOI: 10.1016/j.lfs.2020.118653
  12. Watad A, De Marco G, Mahajna H, et al. Immune-Mediated Disease Flares or New-Onset Disease in 27 Subjects Following mRNA/DNA SARS-CoV-2 Vaccination. Vaccines (Basel) 2021;9(5). DOI: 10.3390/vaccines9050435
  13. Maleki A, Look-Why S, Manhapra A, et al. COVID-19 recombinant mRNA vaccines and serious ocular inflammatory side effects: real or coincidence? J Ophthalmic Vis Res 2021;16(3):490–501. DOI: 10.18502/jovr.v16i3.9443
  14. Cela D, Brignole-Baudouin F, Labbé A, et al. The trabecular meshwork in glaucoma: an inflammatory trabeculopathy? J Fr Ophtalmol 2021;44(9):e497–e517. DOI: 10.1016/j.jfo.2021.09.001
  15. Angeli F, Spanevello A, Reboldi G, et al. SARS-CoV-2 vaccines: lights and shadows. Eur J Intern Med 2021;88:1–8. DOI: 10.1016/j.ejim.2021.04.019
  16. Fowler N, Mendez Martinez NR, Pallares BV, et al. Acute-onset central serous retinopathy after immunization with COVID-19 mRNA vaccine. Am J Ophthalmol Case Rep 2021;23:101136. DOI: 10.1016/j.ajoc.2021.101136
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.